$12.38
2.29% yesterday
NYSE, Nov 15, 10:10 pm CET
ISIN
US30050B1017
Symbol
EVH
Sector
Industry

Evolent Health Inc Class A Target price 2024 - Analyst rating & recommendation

Evolent Health Inc Class A Classifications & Recommendation:

Buy
94%
Hold
6%

Evolent Health Inc Class A Price Target

Target Price $26.14
Price $12.38
Potential
Number of Estimates 14
14 Analysts have issued a price target Evolent Health Inc Class A 2025 . The average Evolent Health Inc Class A target price is $26.14. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 16 Analysts recommend Evolent Health Inc Class A to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Evolent Health Inc Class A stock has an average upside potential 2025 of . Most analysts recommend the Evolent Health Inc Class A stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 1.96 2.56
45.26% 30.36%
EBITDA Margin 7.85% 6.69%
11.38% 14.80%
Net Margin -7.50% -2.50%
340.60% 66.65%

14 Analysts have issued a sales forecast Evolent Health Inc Class A 2024 . The average Evolent Health Inc Class A sales estimate is

$2.6b
Unlock
. This is
3.89% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.6b 4.48%
Unlock
, the lowest is
$2.5b 3.48%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $2.0b 45.26%
2024
$2.6b 30.36%
Unlock
2025
$2.9b 14.60%
Unlock
2026
$3.3b 14.12%
Unlock
2027
$4.0b 18.87%
Unlock
2028
$4.7b 17.21%
Unlock

14 Analysts have issued an Evolent Health Inc Class A EBITDA forecast 2024. The average Evolent Health Inc Class A EBITDA estimate is

$171m
Unlock
. This is
31.14% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$236m 80.64%
Unlock
, the lowest is
$160m 22.54%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $154m 61.79%
2024
$171m 11.11%
Unlock
2025
$231m 34.67%
Unlock
2026
$292m 26.73%
Unlock
2027
$350m 19.70%
Unlock
2028
$426m 21.64%
Unlock

EBITDA Margin

2023 7.85% 11.38%
2024
6.69% 14.80%
Unlock
2025
7.86% 17.49%
Unlock
2026
8.73% 11.07%
Unlock
2027
8.79% 0.69%
Unlock
2028
9.13% 3.87%
Unlock

9 Evolent Health Inc Class A Analysts have issued a net profit forecast 2024. The average Evolent Health Inc Class A net profit estimate is

$-64.0m
Unlock
. This is
38.83% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$8.1m 107.69%
Unlock
, the lowest is
$-104m 1.10%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-147m 540.00%
2024
$-64.0m 56.51%
Unlock
2025
$-940k 98.53%
Unlock
2026
$38.7m 4,214.89%
Unlock
2027
$41.4m 7.03%
Unlock
2028
$143m 244.47%
Unlock

Net Margin

2023 -7.50% 340.60%
2024
-2.50% 66.65%
Unlock
2025
-0.03% 98.80%
Unlock
2026
1.16% 3,966.67%
Unlock
2027
1.04% 10.34%
Unlock
2028
3.06% 194.23%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.28 -0.56
540.00% 56.25%
P/E negative
EV/Sales 0.84

9 Analysts have issued a Evolent Health Inc Class A forecast for earnings per share. The average Evolent Health Inc Class A <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.56
Unlock
. This is
38.46% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.07 107.69%
Unlock
, the lowest is
$-0.90 1.10%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.28 540.00%
2024
$-0.56 56.25%
Unlock
2025
$-0.01 98.21%
Unlock
2026
$0.34 3,500.00%
Unlock
2027
$0.36 5.88%
Unlock
2028
$1.24 244.44%
Unlock

P/E ratio

Current -13.56 50.35%
2024
-22.24 64.01%
Unlock
2025
-1,508.84 6,684.35%
Unlock
2026
36.81 102.44%
Unlock
2027
34.39 6.57%
Unlock
2028
9.98 70.98%
Unlock

Based on analysts' sales estimates for 2024, the Evolent Health Inc Class A stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.87 59.53%
2024
0.84 3.36%
Unlock
2025
0.73 12.74%
Unlock
2026
0.64 12.38%
Unlock
2027
0.54 15.87%
Unlock
2028
0.46 14.70%
Unlock

P/S ratio

Current 0.59 67.43%
2024
0.56 3.74%
Unlock
2025
0.49 12.74%
Unlock
2026
0.43 12.38%
Unlock
2027
0.36 15.87%
Unlock
2028
0.31 14.70%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today